Qual é o preço para Walvax Biotechnology Co., Ltd. (300142)

O preço para Walvax Biotechnology Co., Ltd. (300142) é $2.21

Qual é a capitalização de mercado para Walvax Biotechnology Co., Ltd. (300142)

A capitalização de mercado para Walvax Biotechnology Co., Ltd. (300142) é $3.54B

Walvax Biotechnology Co., Ltd. (300142) Desdobramentos de Ações

Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.

Ano	Desdobramento	Multiplicador	Multiplicador cumulativo
Não há dados suficientes para as datas fornecidas.

Ano

Desdobramento

Multiplicador

Multiplicador cumulativo

Não há dados suficientes para as datas fornecidas.

Empresa	Número de desdobramentos de ações	Multiplicador cumulativo	País
MERCK Kommanditgesellschaft auf Aktien MER.SW	0	-	DE
Merck KGaA MRK.DE	0	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0	-	JP
Galderma Group AG GALD.SW	0	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	5	x119	IN

Empresa

Número de desdobramentos de ações

Multiplicador cumulativo

País